New approaches in the treatment of non-small cell lung cancer: Taxanes in the treatment of NSCLC: Pathways to progress

Lung Cancer

Volumn 38, Issue 1 SUPPL., 2002, Pages

  Kris, Mark G ^a   Tonato, Maurizio ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b University Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; ONYX 015; PACLITAXEL; TAXANE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; TAXOIDS; TREATMENT OUTCOME;

EID: 0036920284     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00319-7     Document Type: Editorial

References (19)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics 2002. CA Cancer J. Clin. 52:2002;23-47.
2. Non-Small Cell Lung Cancer Co-operative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
3. Shepherd F., Dancey J., Ramlau R., et al. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103.
4. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 18:2000;2354-2362.
5. Roskowski K., Pluzanska A., Krzakowski M., et al. A mulitcenter randomized phase III study of docetaxel plus best supportive care in chemotherapy-naive patients with metastatic or non-resectable non-small cell lung cancer (NSCLC). Lung Cancer. 27:2000;145-157.
6. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346:2002;92-98.
7. Rodriguez J., Pawel J., Pluzanska A., et al. A multicenter, randomized phase III study of docetaxel+cisplatin (DC) and docetaxel+carboplatin (DCb) vs. vinorelbine+cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;20a. Abstract 1252.
8. Belani C., Lynch T. Docetaxel in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin. Oncol. 28:(Suppl 2):2001;10-14.
9. Mattson K., Ten Velde G., Krofta K., et al. Taxotere as neoadjuvant therapy for radically treatable stage III NSCLC: preliminary results of an international phase III study. Proc. Am. Soc. Clin. Oncol. 17:1999;494a. abstract 1904.
10. Mattson K., Ten Velde G., Krofta K., Cour-Chabernaud V., Abratt R. Early results of an international phase III study evaluating Taxotere as neo-adjuvant therapy for radically-treatable stage III NSCLC. Lung Cancer. 29:2000;90. Abstr 295, Suppl 1.
11. Gandara D.R., Lovato L.C., Albain K.S., et al. Pathological stage IIIb non-small cell lung cancer (NSCLC): prolonged survival with consolidation of docetaxel following concurrent chemoradiotherapy (SWOG 9504). Lung Cancer. 29:2000;92. Abstr 302, Suppl 1.
12. Gaspar L, Gandara D, Chansky K, et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): Patterns of failure and updated survival. Am Soc Clin Oncol 2001;20 (Abstract 1255).
13. Kelly K., Crowley J., Bunn P.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19:2001;3210-3218.
14. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;1227. Abstract.
15. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 357:2001;1478-1484.
16. Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7:2001;1204-1213.
17. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer. 8:2001;3-9.
18. Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 20:2001;7. Abstract.
19. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: Part II. J. Clin. Oncol. 20:2002;3016-3028.